Citations

Clear

114 citation(s) found for "Scott, Michael".

Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics
Nabbout, Rima , Sullivan, Joseph , Auvin, Stéphane , Cross, J. Helen , Devinsky, Orrin , Guerrini, Renzo, Knupp, Kelly G. , Perry, Μ. Scott , Sánchez-Carpintero, Rocı́o , Scheffer, Ingrid E., Morita, Diego, Healy, Patrick, Langlois, Mélanie , Lagae, Lieven , Scheffer, Ingrid E. , Gil-Nagel, Antonio , Knupp, Kelly G , Perry, Michael Scott , Sánchez-Carpintero, Rocío , Schoonjans, An-Sofie , Specchio, Nicola , Strzelczyk, Adam , Wheless, James W , Wirrell, Elaine C , Lothe, Amélie , Lagae, Lieven , Auvin, Stéphane , Devinsky, Orrin , Cross, Helen J , Scheffer, Ingrid E , Gil‐Nagel, António , Guerrini, Renzo , Specchio, Nicola , Wheless, James W. , Wirrell, Elaine , Morita, Diego A. , Langlois, Mélanie

Mayo Clinic

Epilepsia Open | August 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi4.70340 | PMID 42632015 Get It

Abstract Objective To assess the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) stratified by age, number of previously attempted antiseizure medications (ASMs), and SCN1A pathogenic variant status. Methods In this post hoc analysis, data from three randomized controlled trials (RCTs) in patients with DS (2–18 years) were pooled and stratified by age (<4; ≥4 years), number of previous ASMs (1–3; 4–6; ≥7), and SCN1A pathogenic variant status ( SCN1A +; SCN1A −). Stratified groups were assessed and compared with the pooled placebo group (change in monthly convulsive seizure frequency [MCSF], longest convulsive seizure‐free interval, and Clinical Global Impression–Improvement [CGI–I] scale scores rated by parents/caregivers and investigators), and safety (treatment‐emergent adverse events [TEAEs]: frequency, days to onset, and proportion resolved). Results Among 348 patients included in the RCTs, 216 were randomized to fenfluramine (0.7 mg/kg/day, n = 88; 0.4 mg/kg/day [with stiripentol], n = 43; 0.2 mg/kg/day, n = 85) and 132 to placebo. Compared with placebo, fenfluramine treatment (all doses combined) resulted in greater MCSF reductions, greater increases in longest convulsive seizure‐free intervals, and a higher proportion of parents/caregivers and investigators reporting clinically meaningful improvement (“Much Improved”, “Very Much Improved”) on CGI–I scores across all stratified groups. CGI–I scores were consistent across fenfluramine doses in most stratified groups, but patients with the fewest number of previous ASMs had the greatest frequency of clinically meaningful improvement on investigator‐rated CGI–I scores. Safety outcomes were similar across all strata. Most TEAEs resolved by end‐of‐study. Significance Fenfluramine treatment was associated with improved seizure outcomes and global functioning compared with placebo regardless of age, number of previous ASMs, and SCN1A status in patients with DS. Fenfluramine was well‐tolerated; no new safety signals were identified. Further studies with larger sample sizes (including adults) and a priori inferential analyses of stratified groups are warranted. Plain Language Summary Patients with Dravet syndrome struggle with seizures and everyday life. In three studies, patients aged 2–18 years received fenfluramine or placebo (sugar pill). Fenfluramine lowered seizures without many side effects. Researchers combined results from these studies to see how fenfluramine worked in different patient groups based on age, number of previous medications, and a gene called SCN1A . They looked at seizure reduction and whether doctors felt patients had improved. In all groups, fenfluramine worked better than placebo, with similar side effects. Researchers believe fenfluramine helped these patients, but some groups were small, so these results need to be confirmed.
Variability in recommending epilepsy surgery across Level IV epilepsy centers in the United States
Caraway, Avery R. , McNamara, Nancy A. , Knox, Andrew , Samanta, Debopam , Wolf, Steven M. , Novotny, Edward J., Ostendorf, Adam P. , Eschbach, Krista , Depositario‐Cabacar, Dewi F. , Pichon, Pilar, Auguste, Kurtis I., Bernardo, Danilo , Singh, Rani K., Ciliberto, Michael A., Reddy, Shilpa B., Arredondo, Kristen H. , Marashly, Ahmad , Galan, Fernando N., Armstrong, Dallas M., Wagner, Janelle L. , Wong-Kisiel, Lily C. , Bolton, Jeffrey B., Lin, Jenny, Coryell, J., Perry, Μ. Scott , Group, the rest of the PERC Surgery Special Interest, Galán, Fernando , Knox, Andrew T , Eschbach, Krista , Bernardo, Danilo , Grinspan, Zachary , Abel, Taylor J , Perry, Michael Scott , Galan, Fernando N , Wolf, Steven , McNamara, Nancy A., Novotny, Edward J. , Depositario‐Cabacar, Dewi, Karakas, Cemal , Auguste, Kurtis I. , Javarayee, Pradeep , Singh, Rani K., Ciliberto, Michael A. , Reddy, Shilpa B. , Armstrong, Dallas , Wong‐Kisiel, Lily C. , Bolton, Jeffrey , Grinspan, Zachary M. , Abel, Taylor J. , Coryell, Jason

Mayo Clinic

Epilepsia | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70440 | PMID 42621761 Get It

Abstract Objective Surgery is an effective, yet underutilized treatment for children with drug‐resistant epilepsy. Although predictors of surgical outcomes are well described, the decision to recommend surgery varies by institution. We aim to evaluate the rates of not recommending surgery, identify associated patient characteristics, and quantify variability across centers. Methods We queried the Pediatric Epilepsy Research Consortium Surgery database, a prospective multicenter cohort of children (0–18 years) undergoing initial evaluation for epilepsy surgery. Patients with documented surgical decisions were included. Demographic, clinical, and presurgical evaluation variables were compared by surgical recommendation status. Logistic regression identified factors associated with not recommending surgery. Mixed‐effects models quantified between‐center variability. Results Among 2480 patients across 29 centers, 532 (21%) were not recommended epilepsy surgery (median center rate 17%, interquartile range [IQR] 10%–28%). After accounting for patient characteristics associated with surgical candidacy, substantial variation in decision‐making remained across centers, with a median twofold difference in the odds of not recommending surgery between otherwise similar patients evaluated at different institutions (Median Odds Ratio = 2.25; Intraclass Correlation Coefficient = .18). The clinical characteristics most strongly associated with not recommending surgery included monthly or less frequent seizures (odds ratio [OR] 2.17, 95% confidence interval [CI] 1.75–2.69), non‐structural etiology (OR 2.02, 95% CI 1.56–2.61), and taking ≤2 anti‐seizure medications (ASMs) (OR 1.67, 95% CI 1.34–2.08, all p 's < .01). These characteristics showed minimal clustering across centers (ICCs < .05). Significance One in five children evaluated for epilepsy surgery are not recommended to pursue surgical treatment. Although clinical factors influence decision‐making, they do not explain the substantial variation in recommendations across pediatric epilepsy centers. Similar children evaluated at different institutions had significant differences in the odds of not being recommended surgery, suggesting that institutional decision‐making contributes importantly to surgical candidacy.
Effect of time to palliative epilepsy surgery on outcomes
Crutcher, Robert M. , Horvat, David , Caraway, Avery R. , Arredondo, Kristen H. , Abel, Taylor J. , Agarwal, Nitin , Alexander, Allyson , Armstrong, Dallas , Auguste, Kurtis I. , Bernardo, Danilo , Bolton, Jeffrey , Bonda, David , Depositario‐Cabacar, Dewi F. , Groves, Aran, Hauptman, Jason S. , Knox, Andrew , Lin, Jenny, McGoldrick, Patricia E. , Miller, D. , Ostendorf, Adam P. , Pichon, Pilar, Reddy, Shilpa B. , Samanta, Debopam , Singh, Rani K. , Wagner, Janelle L. , Galán, Fernando , Perry, Μ. Scott , Ciliberto, Michael A. , Horvat, David E , Alexander, Allyson L , Armstrong, Dallas Michael , Depositario Cabacar, Dewi Frances , Eschbach, Krista , Gaillard, William D , Hauptman, Jason , Javarayee, Pradeep K , Karakas, Cemal , Knox, Andrew T , McGoldrick, Patricia E , Miller, Derryl J , Novotny, Edward J , Ostendorf, Adam P , Pichon, Pilar D , Reddy, Shilpa B , Samanta, Debopam , Singh, Rani K , Wagner, Janelle , Wolf, Steven , Wong-Kisiel, Lily C. , Galan, Fernando N , Perry, Michael Scott , Ciliberto, Michael A , Auguste, Kurtis I , Arredondo, Kristen H , Abel, Taylor J , Agarwal, Nitin , Bernardo, Danilo , Crutcher, Robert , Bonda, David , Depositario‐Cabacar, Dewi, Eschbach, Krista , Gaillard, William D. , Javarayee, Pradeep , Karakas, Cemal , Novotny, Edward J. , Wolf, Steven M. , Wong‐Kisiel, Lily C.

Mayo Clinic

Epilepsia | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70379 | PMID 42545811 Get It

Abstract Objective Epilepsy duration is a modifiable risk factor in the outcome of definitive epilepsy surgery; however, an analogous effect in palliative procedures has not been shown. We reviewed the Pediatric Epilepsy Surgery Database data for an association between epilepsy duration and seizure reduction in palliative procedures. Methods Patients enrolled between January 2018 and April 2025 who underwent their first epilepsy surgery with palliative intent with 6 months of follow‐up were included. Procedures included neuromodulation, corpus callosotomy, hemispherotomy, lesionectomy, and lobectomy where surgical intent was not seizure freedom. Outcomes of seizure freedom, 90% seizure reduction, and 50% seizure reduction were considered at 6–12 months and >12 months from surgery. Duration from epilepsy onset to surgery was compared for patients above and below each outcome threshold at each time point. Logistic regression analysis for the association between epilepsy duration and seizure reduction adjusted for potential confounders including procedure type, etiology, and other clinical factors. Logistic regression analysis was performed on the overall cohort and subgroups of patients with each procedure. Results A total of 588 patients were included. Initial univariate analysis suggested that epilepsy duration at time of surgery was significantly associated with seizure freedom and 90% seizure reduction at both 6–12 months and >12 months. After adjusting for confounders, only seizure freedom at >12 months was significantly associated with duration of epilepsy. When individual procedures were considered, only lobectomy was sensitive to duration of epilepsy in multivariate analysis, with significant impacts on >50% and >90% seizure reduction at >12 months. Lesional epilepsy predicted seizure freedom at >12 months. Neuromodulation and corpus callosotomy were less likely to achieve seizure reduction than other procedures. Significance We did not find an association between early epilepsy surgery and seizure reduction. This reflects the heterogeneity of our population, including different types of surgical procedures and lesional and nonlesional epilepsies.
“Heart Sign” with Double Aortic Arch
Binder, Michael Scott , Majdalany, David , Majdalany, David S , Binder, Michael Scott

Mayo Clinic

Diagnostics | July 14, 2026 | Volume: 16 | Issue: 14 | Pages: 2188

10.3390/diagnostics16142188 | PMID 42510053 Get It

Double aortic arches are rare congenital malformations resulting from persistence of the right and left aortic arches, as opposed to normal regression of the left aortic arch. These vascular malformations can cause vascular rings since they encompass the trachea and esophagus, and lead to swallowing difficulties or respiratory difficulties from extrinsic compression. Typically, these are diagnosed in childhood but rarely may present in adults. In the presence of symptoms, which require formal gastrointestinal and pulmonary evaluation, surgical resection of the nondominant arch is typically recommended to release the vascular ring. Monitoring of the carotid and subclavian vasculature is performed intraoperatively to ensure distal perfusion is not affected following distal ligation of the arch.
Zorevunersen Demonstrates Potential as a Disease-modifying Therapy in Patients with Dravet Syndrome Through Durable Seizure Reduction and Improvements in Cognition, Behavior, and Quality of Life Through 36 Months of Treatment in Open-label Extension Studie
Laux, Linda, Cross, J Helen, Perry, M Scott, Sullivan, Joseph, Desurkar, Archana , Roberts, Colin M., Wheless, James W., Ventola, Pam, Werneburg, Brian, Lynch, Jessie, Wang, Fei, Parkerson, Kimberly A. , Ticho, Barry, Cross, J. Helen , Cross, Helen J , Laux, Linda , Knupp, Kelly G. , Brunklaus, Andreas , Perry, Michael Scott , Schreiber, John R. , Roberts, Colin, Wheless, James W. , Wirrell, Elaine , Ticho, Barry

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217057 Get It

Virtual AI-informed immunocyte profiling (VAIP) from H&E as a predictor of multi-cancer prognosis.
Jana, Mayukhmala , Aggarwal, Arpit, Shanbhogue, Nikhil, Pathak, Tilak, Toro, Paula , Lewis, James S., Wasman, Jay, Teknos, Theodoros N., Pan, Quintin, Shi, Qiuying , Schmitt, Nicole Cherie, Saba, Nabil F., Oršulić, Sandra , Bazzaro, Martina , Corredor, Germán, Madabhushi, Anant, Aggarwal, Arpit , Badve, Sunil , Thorat, Mangesh A. , Lewis, James S. , Pan, Quintin , Schmitt, Nicole C. , Steward-Tharp, Scott Michael , Saba, Nabil F. , Corredor, Germán

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 3118-3118

10.1200/jco.2026.44.16_suppl.3118 Get It

3118 Background: Improved risk stratification is critically needed across multiple cancers to guide treatment decisions. This includes reducing overtreatment in Ductal Carcinoma in Situ (DCIS), addressing late recurrence risk in estrogen receptor-positive/lymph node-negative (ER+/LN-) breast cancer (BC), and refining prognosis in head & neck squamous cell carcinomas (HNSCC), and high-grade serous ovarian carcinoma (HGSOC). Tumor-infiltrating lymphocytes (TILs) reflect anti-tumor immunity, whereas tumor-associated macrophages (TAMs) polarize toward anti-tumor M1-like (CD68+) or immunosuppressive M2-like (CD163+) phenotypes. Integrating TILs with TAM polarization markers may better capture inflammatory balance and improve outcome prediction. We developed a hematoxylin and eosin (H&E)-only AI method (VAIP) to quantify TILs and virtual CD68/CD163 TAMs to develop multi-cancer based potential prognostic models. Methods: TILs were detected on H&E with HoVer-UNet, and virtual CD68 and CD163 macrophages were inferred with VISTA. In cancer regions, we computed cell densities and immune-balance ratios and trained cancer-specific Cox models with compact feature sets (DCIS 6; HGSOC 7; ER+ 4; HNSCC 4). Prognostic stratification used disease-free survival (DFS) for DCIS (N=273), HGSOC (training N=165, independent test N=220), and ER+ BC (training N=144, test N=622), and overall survival (OS) for HNSCC (N=77), reflecting clinical endpoints. Evaluation used cross-validation for cohorts without an external test set (DCIS, HNSCC) and independent training and testing when independent cohort was available (HGSOC, ER+). Results: Risk stratification performance across cancer types is in Table 1. The DCIS model used 6 features, largely TIL-macrophage contrast ratios (TIL/M2, TIL/M1). HGSOC used 7 features with a similar ratio-heavy immune-balance signature, plus macrophage-normalized density and polarization metrics (e.g., M1/N, M/N). In contrast, ER+ BC and HNSCC achieved best performance with 4 features dominated by macrophage measures, particularly M2 density and the M1/M2 ratio. Across sites, CD163-related macrophage metrics and immune-balance ratios were consistently informative. Conclusions: Integrating H&E-visible TILs with virtual CD68/CD163 TAMs enables fully automated, H&E-only prognostic biomarkers that stratify OS and DFS across multiple cancers, demonstrating consistent prognostic value in DCIS, ER+ BC, HGSOC, and HNSCC. These findings support further study of this histomorphometric risk classifier through broader external and prospective validation. Performance across cancer types. Cancer Type Cohort C-index HR [95% CI] p-value DCIS All 0.616 1.76 [1.20-2.59] <0.001 DCIS RT/No-treatment 0.624 1.94 [1.15-3.26] 0.003 HGSOC Test 0.553 1.38 [1.02-1.87] 0.030 ER+ BC Test 0.577 1.51 [1.00-2.28] 0.004 HNSCC All 0.603 1.92 [1.03-3.36] 0.012
Sex-Based Patterns and Trends in Transcatheter Aortic Valve Implantation
Nicolas, Johny, Gelijns, Annetine C., Moskowitz, Alan J., Leon, Martin B., Mehran, Roxana, Chikwe, Joanna, Mack, Michael J., Guerrero, Mayra E., Makkar, R, Jessup, Mariell, O’Gara, Patrick T., Egorova, Natalia, Nicolas, Johny , Gelijns, Annetine C. , Moskowitz, Alan J. , Leon, Martin B. , Mehran, Roxana , Chikwe, Joanna , Mack, Michael J. , Guerrero, Mayra , Makkar, Raj , Jessup, Mariell , O’Gara, Patrick T. , Egorova, Natalia

Mayo Clinic

JAMA Cardiology | May 6, 2026 | Volume: 11 | Issue: 6 | Pages: 496

10.1001/jamacardio.2026.0941 | PMID 42090130 Get It

Importance Sex-related disparities affect diagnosis, referral, and prognosis of aortic valvular diseases. Contemporary US data on transcatheter aortic valve implantation (TAVI) by sex are limited. Objective To characterize 10-year trends in TAVI use, periprocedural complications, and long-term outcomes among Medicare beneficiaries, stratified by sex. Design, Setting, and Participants This nationwide, retrospective, population-based cohort study used US Medicare claims data from fee-for-service beneficiaries discharged after TAVI from January 1, 2013, to December 31, 2022. The median follow-up time was 2.19 (IQR, 0.94-3.79) years. Exclusions included patients who had concomitant valve surgery, infective endocarditis, valve-in-valve TAVI, transapical TAVI, TAVI for pure aortic insufficiency, or later conversion to Medicare Advantage. Analyses were conducted between October 1, 2024, and April 1, 2025. Exposure TAVI. Main Outcomes and Measures The primary outcome was all-cause mortality. Secondary outcomes included periprocedural mortality, vascular complications, acute kidney injury, major or life-threatening bleeding, stroke, acute myocardial infarction (AMI), permanent pacemaker implantation (PPI), and hospitalization for heart failure (HF). Adjusted odds ratios (AORs) and hazard ratios (AHRs) with 95% CIs were estimated. Results The study included 314 123 patients (141 233 women [45.0%] and 172 890 men [55.0%]). Women were older than men (mean [SD] age, female: 80.3 [7.8] years; male: 79.4 [7.7] years; standardized mean difference, 12%). The proportion of female patients who underwent TAVI declined from 47.6% in 2013 to 43.6% in 2022 ( P &amp;lt; .001). Compared with men, women had higher periprocedural mortality (2.5% vs 2.2%; AOR, 1.20 [95% CI, 1.14-1.26]), vascular complications (5.8% vs 3.6%; AOR, 1.65 [95% CI, 1.60-1.71]), and bleeding (10.4% vs 6.8%; AOR, 1.67 [95% CI, 1.62-1.71]) but less PPI (16.9% vs 20.0%; AOR, 0.81 [95% CI, 0.79-0.82]). Long-term mortality was lower in female patients (AHR, 0.92; 95% CI, 0.91-0.93), although their risks of HF hospitalization, AMI, stroke, and bleeding were higher. Conclusions and Relevance Among Medicare beneficiaries, women constituted a progressively declining proportion of patients treated with TAVI, experienced more periprocedural complications, and demonstrated modestly better long-term survival compared with men. Further work is needed to understand factors influencing these trends and to refine sex-specific strategies for optimal outcomes.